Science Corporation, a startup focused on innovative brain-computer interfaces (BCI), received approval from Europe’s medical device authority to commence sales of a device that restores vision impaired by age-related macular degeneration.

The firm announced that the device, named PRIMA, has also obtained a designation from the US Food and Drug Administration, marking the initial step toward a fast-tracked regulatory review, which may allow the device to be utilized for treating two rare forms of blindness.

Countless individuals globally experience age-related macular degeneration, which deteriorates the light-sensitive cells at the rear of the eyes, complicating reading and facial recognition.

For utilizing the device, patients experiencing this vision loss undergo a one-hour outpatient operation that inserts a small chip at the back of their eye. Subsequently, they wear glasses equipped with a camera that relays their surroundings to the chip. Max Hodak, the founder and CEO of Science Corp., states that this product restores functional vision to individuals who have lost it.

“One of our patients in France recently completed a 300-page novel and sent us the book,” Hodak mentioned to TechCrunch. “We have a sketch on the wall [that] one of our patients drew of the Sydney Opera House. There are videos of patients engaging in crossword puzzles and completing Sudoku.”

Hodak is recognized as the co-founder and former president of Neuralink, Elon Musk’s BCI startup. He departed in 2021 to establish Science Corp., with ambitions to invent a new BCI that combines silicon chips with living cells. However, the company first needed to validate its methods and create a viable business.

“What this field requires is a company generating $100 million per year in revenue,” Hodak commented. “There’s a risk of a downturn affecting the entire industry, so we believe it’s crucial to establish a sustainable business as we advance these long-term technologies.”

Hodak and his team are confident that this sustainable business will come from restoring sight to the blind, particularly patients whose conditions arise from issues with the light-sensitive cells in the back of the eye. After investigating various methods, they concluded that Pixium, a French company that created the PRIMA technology, was on the right track and acquired the company in 2024. Science Corp. utilized its internal platform to develop the documentation and enhance the product in preparation for regulatory approval and market entry.

Each PRIMA device is anticipated to be priced in the hundreds of thousands of dollars; Science Corp. and its medical collaborators in Europe are currently negotiating with healthcare providers regarding reimbursement. The company is setting the stage to start offering PRIMA in Germany, where its clinical trials took place, and the first procedure could occur in September.

Science Corp. plans to keep enhancing the vision capabilities of PRIMA with a new chip, alongside modifying the design of its glasses, which presently necessitate a battery pack to function. The objective is to create something akin to Meta’s AR glasses, although the power and processing demands for PRIMA are greater.

Science Corp. is also collaborating with Dr. Murat Günel, chair of Yale Medical School’s neurosurgery department, to devise procedures for human trials of a directly implanted bio-hybrid brain sensor.

Hodak asserts that launching PRIMA is “the most critical endeavor for the company, because we can’t pursue the bio-hybrid initiatives in the long term without a robust vision business. That’s what mainly finances everything else — that’s the aspect investors understand how to create financial models around.”